AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS)
Stroke
Southern Medical University, ChinaCell therapyPhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 65/ 100
Competitive context
141 Active assets in the Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivaroxaban China National Center for Cardiovascular Diseases | Phase 4 | BBB |
Tenecteplase Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
Acetylsalicylic Acid China National Center for Cardiovascular Diseases | Phase 4 | BB |
Ticagrelor Assistance Publique - Hôpitaux de Paris | Phase 4 | BB |
WARFARIN China National Center for Cardiovascular Diseases | Phase 4 | BB |
View all 50 →
Same molecule, other indications
AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →